-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target

Benzinga·11/06/2025 00:18:09
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.